Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer and principal financial and accounting officer of Iovance Biotherapeutics, Inc. (the “ Company”), provided the Company with written notice under his Executive Employment Agreement, dated November 23, 2020, that he would resign from the Company, effective July 10, 2025, to pursue other opportunities. SIGNATURES